Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)

China flag China · Delayed Price · Currency is CNY
29.55
-0.62 (-2.06%)
At close: Mar 9, 2026
Market Cap1.71B +40.6%
Revenue (ttm)174.00M -28.2%
Net Income-49.88M
EPS-0.90
Shares Out55.19M
PE Ration/a
Forward PEn/a
Dividend0.34 (1.15%)
Ex-Dividend DateOct 24, 2025
Volume860,577
Average Volume696,451
Open29.87
Previous Close30.17
Day's Range28.85 - 29.97
52-Week Range17.50 - 36.00
Beta0.38
RSI46.24
Earnings DateApr 11, 2026

About SHA:688217

Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of molecular diagnosis of infectious diseases in China. The company offers self-operated reagents, purchased preparations, scientific research services, and testing services for blood diseases, solid tumors, infectious diseases and lymphoma. Shanghai Rightongene Biotechnology Co., Ltd. was founded in 2012 and is based in Shanghai, China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 385
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688217
Full Company Profile

Financial Performance

In 2025, SHA:688217's revenue was 174.00 million, a decrease of -28.19% compared to the previous year's 242.31 million. Losses were -49.88 million, 216.4% more than in 2024.

Financial Statements